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ABSTRACT 
Since their discovery breast prostheses have been criticized 
for being responsible for triggering systemic autoimmune disease. 
The presence of breast implants causes a natural foreign body 
reaction characterized by the infiltration of macrophages and T-cells. 
In order to understand which immunological pathways could be 
responsible for giving rise to, and the development of, connective 
tissue disease such as systemic sclerosis, I considered the cells and 
cytokines involved, focusing on the relationship between tissue 
growth factor-?, interleukin (IL)-1, IL-6 and T helper 17 and/or T 
regulatory cells, and their effects on the different steps of capsular 
tissue formation. A disturbance in the modulation of these key 
cytokines may be responsible, in susceptible individuals, for a 
perpetuation of the inflammatory reaction which can locally lead to 
capsular contracture and at the systemic level may contribute to 
triggering autoimmune diseases. 
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Sin dalla loro creazione le protesi mammarie sono state 
considerate responsabili della possibile insorgenza di malattie 
autoimmuni sistemiche. La presenza di protesi mammarie provoca 
una reazione naturale da corpo estraneo caratterizzata 
dall’infiltrazione di macrofagi e linfociti T. Al fine di capire i 
meccanismi immunologici che stanno alla base dell’insorgenza e 
dello sviluppo di malattie, come la sclerodermia, ho considerato le 
cellule e le citochine coinvolte, focalizzando l’attenzione sulla 
relazione tra il TGF-?, l’interleuchina (IL)-1, IL-6, i T helper 17 e/o 
le cellule T regolatrici, e il loro effetto sulle diverse fasi di 
formazione del tessuto capsulare. Un disturbo nella modulazione di 
queste citochine chiave può essere responsabile, in soggetti sensibili, 
di una cronicizzazione della reazione infiammatoria, che può 
localmente portare a contrattura capsulare e a livello sistemico può 
contribuire a innescare malattie autoimmuni. 
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INTRODUCTION   
 
Almost ten years ago, during my medical graduation, I started 
to consider that in these last centuries, especially in the latter, the 
chemical development promotes the research of biologically 
compatible materials which could permit to restore the body image, 
and consequently the psychological point of view, of patients 
affected by any kind of impairments.  
In this atmosphere many scientists tried to find a good 
substitute of the breast with the aim of restore its natural shape, 
firstly using external prostheses which could give back only the 
aesthetic point of view and later using implants, inserted in women’s 
body, which could restore not only the tactile sensation, but also the 
psychological image. 
The history of the actual mammary implants begun at the end 
of nineteenth century when Vincenz Czerny and Robert Gersuny 
used the adipose autologous tissue (the first) and liquid paraffin (the 
second one) as filler for breast augmentation  but unfortunately the 
presence of cysts, due to the liquid material, provoked the abandon of 
this late solution. The upcoming silicone and polyurethane foam 
would have changed everything.    
         
              Vincenz Czerny        Robert Gersuny 
??
?
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1. 
 AN OLD PROBLEM: WHICH MATERIAL FOR BREAST PROSTHESES?  
 
1.1 SILICONE: 
 
 
 
Discovered in 1907 by Frederick Kipping and chemically 
known as polydimetilsiloxane, the silicone is a polymer, heat stable, 
microscopically visible as a refractive material. 
Initially not used for medical devices, in 1948, Dow Corning 
Industries created the “Silastic” medical grade that is silicone for 
medical purpose. Since that moment silicone  has been used in many 
medical devices, including artificial valves, joints, needles and teats, 
becoming, in the sixties, the major component of breast implants as 
for the surface as for the content.  
 
Frederick Kipping 
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1.2 POLYURETHANE: 
 
 
 
Discovered in 1947 by Otto Bayer the polyurethane is a 
polymeric material derived by MDI (methylene-diphenil-isocyanate). 
It can be straight, elastic, adhesive, foam etc.   
Being biologically compatible the polyurethane has been used 
in many medical devices as vascular prostheses, inner room of 
artificial hearts and, in plastic surgery, as prosthetic surface of some 
breast implants. 
 
Otto Bayer 
???
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2. 
SILICONE BREAST IMPLANTS: MORPHOLOGICAL FEATURES 
 
2.1 Breast implants: 
Appeared in 1963 as a smooth silicone implant filled by 
liquid silicon, nowadays on the market there are three types of 
prosthetic surface, round or anatomical in shape, featured by the 
presence of silicon outside and inside. 
 
The surface: 
1) Smooth surface characterized by a smooth silicone outside and 
soft cohesive gel for the content. 
Nowadays it’s used mostly as sizer during the surgery, abandoned as 
definitive implant because of the strong foreign body reaction, with 
consequent increased risk of capsular contracture, due to the 
smoothness of the surface. 
 
Smooth surface: E=External side, I=Internal side?
? ?
?
 
Smooth surface?
 
 2) Textured surface, featured by pores or microvilli (depending on 
home manufacturer), allows the implant to be anchored to the 
surrounding tissue and thus to remain in place. These kinds of 
implants have been created in the nineties with the aim of avoiding 
or reducing the inflammatory response to the prostheses. In the first 
years after surgery, the texturization disarranges the collagen fibers 
and reduces the possibility of circular contraction of the capsule. 
 
?
Allergan texturization 
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?
 
Mentor texturization 
 
3) Textured silicone surface coated with polyurethane foam 
characterized by a double surface and cohesive silicone gel inside. 
Made for the recurrence of capsular contracture (the presence of the 
polyurethane supports a longer young inflammatory response 
featured by macrophages and neovascularization). 
 
 
Polyurethane surface 
 
 
???
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The content 
Many researches have been made to find the ideal content 
featured by the compatibility and the right firmness to give a natural 
breast1. Firstly being liquid, the silicone was banned in 1992 in USA 
because of the frequent bleeding from the implants and the potential 
induction of autoimmune connective tissue diseases (CTD). To avoid 
bleeding the manufactures created new kinds of contents, as silicone 
cohesive gel, soft cohesive gel, jaluronic acid, soybean oil and finally 
????????????????????????????????????????????????????????????
??Some reference 'history': Giachero, taking Mutou, recalls how a sort of  silicone 
implants have been used in 1949 by the Japanese scholar Akiyama, who used two 
different types of implants: the first pre-filled with silicone gel, the second can be 
intraoperatively filled with semi-fluid silicone. Mutou himself used these 
prostheses and in a period of 4 years (from 1966 to 1970) submitted 79 patients to 
breast augmentation surgery, and obtained encouraging results in 68 cases. The 
first silicone breast implant appeared on the market in 1963 when Cronin and 
Gerow,  having consulted Braley and remembering the suggestion of Brown et al. 
(1960) of using the silicone breast implants, developed the first silicone implants as 
we know them. This prosthesis, the Cronin implant, presented a silicone shell with 
4 smooth Dacron disks of Dacron with the aim of allowing the adherence to the 
surrounding tissues. The front and rear disks, however, created an intense 
inflammatory response, “recommending” the presence of the only rear one. In 
1965 Arion created the silicone implants filled with saline. In the same years were 
also introduced devices without Dacron, but with a higher mobility; in addition, the 
manufactures made several changes and to the outer surfacehe and to its contents; 
they increased the viscosity of the silicone gel. Industries like Dow Cornig, 
McGhan, etc.., tried to find new shapes: from a round implant to a drop featured by 
low, medium or high profile and round or oval base. Another industry named 
Koken invented a ruse with the aim of decreasing the periprosthetic capsule, but 
the solution was soon abandoned. The idea was of incorporating silicone together 
with oxygen, so the progressive loss of the latter would have reduced the volume 
and the tension of the prosthetic surface and of the capsule itself. Considerable 
efforts were made to improve the volume of filling, just think about Arion (1965) 
and his saline implants; or Becker, who, in 1984, combined the pre-filled and 
refillable implants to obtain the double-lumen ones. These implants were featured 
by two pockets, one filled with a silicone gel and one fillable with saline. All these 
efforts and others have always had the primary purpose of avoiding, or at least 
reducing, the formation of periprosthetic capsule and the risk of its contracture / 
retraction. In 1970 Ashley et al., introduced the polyurethane, decreasing the rate 
of contraction / capsular retraction. Later, in 1989, after the success of this new 
polymer, microstructured or textured implants have been launched on the market. 
These are the devices that the plastic surgeons use in daily practice. Finally, two 
other kind of shells were studied: the prosthesis covered with a film of Carbofilm 
and those in PVP (polyvinylpyrrolidone). The first was based on the belief of the 
extreme biocompatibility of carbon and its consequent ability to reduce the 
capsule. The second has been studied by Menke et al. In a period of 2 years, during 
a perspective survey, the authors observed as the implants filled with PVP were a 
good alternative to the saline ones both for their increased viscosity, both for the 
very satisfactory aesthetic results. 
???
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saline (the latter widely used in these years in USA)2.  Having 
abandoned the soybean oil because of its carcinogenicity not only for 
the patients but also for their children (biodegrading products could 
be eat by the babies during breast feeding)3, and recently having 
excluded jaluronic acid (Macrolane) because of the radiological 
difficulties in cancer diagnoses due to the possible microcalcification 
of  the material, nowadays the most frequent content in Europe, and 
since 2011 in USA, is represented by the silicone cohesive gel that 
avoid bleeding from the implant even in rupture cases. 
 
2.2 Breast prostheses and human body 
Since their introduction many authors have dedicated their 
studies to understand the exact relationship between silicone breast 
implants and human body in order to verify the real compatibility of 
????????????????????????????????????????????????????????????
 ? For a discussion of this topic see also Scarpa C., La reazione periferica alle 
protesi mammarie riempite con silicone e con olio di soia: studio istologico, 
Graduation ( Padua University 2001-2002) pp.13-37. 
??The 'life' of implants filled with soybean oil was very short: in 1995 the company 
Lipomatrix, thinking of the biodegradability of the content, produced a new type of 
prosthesis, called Trilucent (for the presence of a mixture of triglycerides and an 
implant surface radiolucent) filled no more than silicone gel, but of soybean oil. 
Immediately Young (1996) noted how the oil “bleeded” by the prosthesis was 
easily absorbed and metabolized without causing inflammation or foreign body 
reaction. These observation haven’t been confirmed later. Choudhary (2000) found 
not only a foreign body reaction and a significant inflammatory response, due to 
the bleeding and the breaking of Trilucent, but showed that the oil wasn’t  easily 
absorbed staying in place. In the same year Williams published a study on the 
toxicity of soybean oil, indicating the formation of an aldehyde (and other 
products), due to the peroxidation of fatty acids, with potential risk for the patients. 
McArthur (2001) confirmed these measurements suggesting and demonstrating the 
possible genotoxicity of the material that was intact and leaked through the wall of 
the prostheses. Simultaneously Munker (2001) reported that the 55% (56 out of 
88!), of explanted Trilucent, showed a thickening or a change in the color of the 
surface, due to lipid peroxidation. It’s very important, the observation of a 
remarkable adherence of the periprosthetic capsule to the surrounding tissues, 
especially the pectoralis major muscle. Finally McGregor (2002) has highlighted 
the risk of rupture during their removal, due to the ‘Velcro effect’. 
???
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the materials. From this point of view we can find studies about the 
possibility of infection, cancer risk, but most of all about the foreign 
body reaction and the possibility of triggering autoimmune diseases. 
 
2.2.1 The possibility of infection: due to the presence of 
microorganism as Staphylococcus aureus, Staphylococcus 
epidermidis etc.4, it could be promoted by the insertion of the 
implants. A “non sterile” technique or an incision in the axillary fold 
can cause this complication. To avoid this problem many authors5 
have proposed the use of antibiotic solution, with or without 
disinfectant or saline, on the prostheses or locally inserted in the 
????????????????????????????????????????????????????????????
??Since the end of the seventies the commensal bacteria of the human skin were 
identifies to be introduced during surgery. Already in 1979 Coutiss (see http:// 
www.silicone-review.gov.uk/infection/index.htm) recorded the presence of, 
Staphylococcus aureus, a commensal of the human skin and potentially pathogenic 
bacterium, in the 72% of the cases. In the following years Ransjo (1983), 
Freedman (1989), Virden (1992), Brand (1993), and still Poblete (1994), Dobke 
(1995), Ahn (1996) have identified in bacteria, as Staphylococcus aureus, 
epidermidis, Streptococci A and B etc., the cause of implant infection. So it was 
clear the correlation between infection and the formation of periprosthetic capsule 
and its contraction. Initially it was thought that the presence of bacteria could cause 
the formation of  periprosthetic capsule: 10 units that form colonies of bacteria are 
sufficient to give the capsule and 107 to cause the extrusion of the implants, but  
investigators as Kossovsky (1984) showed that the infection could accelerate or 
exacerbate the formation of the capsule, but wasn’t the cause. In 1992 Virden 
identified the presence of bacteria (Staphylococcus epidermidis) in the 56 % of 
implants affected by capsular contracture (15 implants out of 27). Dobke (1995) 
confirmed the previous data, establishing the presence of bacteria with a 
predominance of Staphylococcus epidermidis in 54% of the analyzed implants (81 
of 150). In the 76% of the contracted capsule (62 of 82) were found bacteria. 
Unfortunately the relationship between the implants, the capsule and the bacteria is 
still unclear.?
?? In this regard, in 1981 and then in 1994 Burkhardt noted that the use of 
antibiotics, such as gentamicin and cephalothin, and/or the irrigation with Betadine 
decrease the number of bacteria conducing to the reduction of the capsular 
contracture, also if severe. 
 
???
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breast pocket, or the administration of antibiotic therapy during the 
pre, intra and postoperative period. Unfortunately there are no unique 
guide lines for this complication, and the plastic surgeons can act 
following their preferences. 
 
2.2.2 The cancer risk: hypothesized for years because of the 
silicone products consequent to its fragmentation, it has been 
considered not only for the silicone but also for the polyurethane 
foam and for the soybean oil. 
Nowadays it’s been confirmed only for the Trilucent soybean 
oil prostheses that were abandoned in 1997 causing the necessity of 
substituting the implants with silicone ones. 
Regarding silicone, this material has been studied for years 
and recently reintroduced in USA by the FDA, The American Food 
and Drugs Administration, because of the absence of evidence of an 
increased cancer incidence. 
Same destiny has been reserved for polyurethane foam 
considered responsible for the triggering of cancer due to 2,4 
toluendiamine, derived by the polyurethane fragmentation.  
Nowadays the “cancer risk-polyurethane related” has been 
abandoned: the amount of 2,4 toluendiamine is too low to trigger 
cancer in humans.  
 
 
 
???
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2.2.3 The foreign body reaction 
 
The periprosthetic capsule: 
 
 
 “The formation of a fibrous capsule around a silicone breast 
implant is part of a physiologic reaction….In contrast the formation 
of capsule contracture is a local complication of unknown causes” 
this in Poeppl 2007. Well known as periprosthetic capsule, it is a 
dynamic inflammatory reaction, appeared in the first 20 days after 
surgery and present with any kind of foreign body with the aim of 
isolating the implant from the surrounding tissues. At the beginning 
it’s featured by a macrophagic reaction becoming lymphocytic and 
finally collagenous during the maturation of the capsule, as we see 
later.  
 
???
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Histologically we can distinguish three layers:  
1) the intimal zone,  
2) the intermediate zone,  
3) the transition zone.  
 
The intimal zone: inner compartment directly related to the 
surface of the implant; it is featured by a mono o multilayered 
inflammatory reaction composed by macrophages, fibroblasts and, in 
some cases, a pseudoepithelium named synovial metaplasia.  
 
The intermediate zone: characterized by a variable thickness 
and the presence of collagen fibers, parallel aligned or disarranged 
dependently by prosthetic surface and the age of the implant. At the 
beginning the texturization promotes the disarrangement but, in the 
older capsules, the fibers are parallel aligned increasing the risk of 
capsular contraction.  
 
The transition zone: outer compartment related with the 
surrounding tissues (pectoralis major muscle or mammary gland). 
 
The synovial metaplasia 
In the last 40 years authors like Chase et al., Copeland et al., 
Raso et al., Del Rosario et al., and Wyatt et al. described the synovial 
metaplasia as a typical feature more evident in capsules from 
textured and polyurethane breast prostheses.  
 (?
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According to Chase, Ko and Wyatt the synovial metaplasia 
can be related with the age of the implant, decreasing as the age of 
the implant increase. At the time, the synovial metaplasia was seen as 
having a protective effect against the capsular contracture thanks to a 
biofilm produced by the capsular synovial cell layer at the interface 
with the implant and consisting of chondroitin 4 sulfate and keratin 
sulfate. 
Authors, like Ko and Poeppl found no correlation between the 
presence of this pseudoepithelium and the chemical and physical 
features of the implant’s surface, hypothesizing that only the 
mechanical stress, exerted by the implant on the surrounding tissues, 
could cause it.  
Histologically, in accordance with Raso et al. the synovial 
metaplasia is a proliferation of synovia-like cells arranged in a 
palisade manner in the interface between capsule and implant. Using 
an electronic microscope the cells can be distinguished in:  
macrophage like and fibroblast like. The cells are featured by round 
to oval nuclei and an abundant eosinophilic cytoplasm. 
Multinucleated forms were also found. This membrane may be 
everted on the capsular surface, giving rise to villous hyperplasia. 
The cells are positive to vimentin, lysozyme, CD68, anti-
trypsin, anti-chymotrypsin. 
 ??
?
 
Synovial Metaplasia 
 
The Collagen Fibers 
 Many authors (as Ginsbach, Brand, Bucky, Batra and 
Wyatt) have described a random or multidirectional orientation of the 
collagen bands, associated with textured and polyurethane 
prostheses, becoming parallel with the age of the implant and/or 
sometimes with the mammary massage, a common practice in 
patients after breast reconstruction. This act could cause a separation 
between the capsule and the textured surface of the implant, with a 
consequent straightening of the connective fibers.  
  ?
?
 As Giachero described in 1992, and also in mine 
studies6, the change in the density of the collagen fibers, or fibrosis, 
is a common feature of both silicone and polyurethane implants and 
increases with the age of the prostheses, replacing the inflammatory 
reaction. 
 
Autoimmune disease:  
Known as connective tissue diseases, these pathologies are 
not physiological and have been recently correlated with the 
siliconosis in a new syndrome, described by Shoenfeld et colleagues, 
called ASIA Syndrome. 
ASIA is the acronym for autoimmune/autoinflammatory 
syndrome induced by adjuvants and it comprehends the siliconosis 
mediated by the exposure to silicone (the adjuvant) and featured by 
immune phenomena and clinical symptoms of autoimmune diseases 
such as, for example, body ache, morning stiffness, dry eyes and 
mouth and unexplained fever.  
In a recent paper7 I’ve reviewed the literature since sixties 
‘till today with the aim of finding if the correlation between SBI 
(silicone breast implant) and CTD has been clarified. At the 
beginning there have been few case reports that correlated SBI with 
CTD describing clinical symptoms of unspecified and/or well-
defined autoimmune diseases such as systemic sclerosis (SSc) or 
????????????????????????????????????????????????????????????
?
 See?Scarpa 2002  and 20102. 
7
 See Scarpa 20101. 
 ??
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Sjogren’s syndrome (SS), conditions in which anti-silica antibodies 
or other autoantibodies were detected. 
Later, from 1990 to 2000, there have been experimental 
studies using also animal models (e.g. New Zealand Black mice vs 
BALB/c albino mice). These papers were mostly cross sectional or 
case control based on large groups of patients. In this last group of 
studies autoimmune symptoms, immune cells, including T cells, and 
autoantibodies were analyzed in order to explore the relationship 
between SBIs and the occurrence of CTD.  
Some autoimmune diseases such as the human adjuvant 
disease (HAD), SSc, Rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), morphea, SS, and fibromyalgia were reported 
in association with SBI. 
Notably, some immune abnormalities were found including 
changes in CD4+ T cells and macrophages, autoantibodies such as 
anti-silica and anti-collagen, and to a lesser extent antinuclear  
antibodies (ANA), anti-cardiolipin, anti-tireoglobulin, and anti-
thyroid antibodies and rheumatoid factor. 
However, the studies on the association between breast 
implants and CTD are contradictory and failed to explain why in 
some patients SBI may stimulate CTD and the removal of these 
implants may reverse the disease after a long time ranging from 
months to years. 
Proinflammatory biomarkers, including Heat Shock Protein 
(HSP) 60, Myeloid Related Proteins (MRP) 8-14, procollagen III, 
 ??
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circulating immune complexes and antiphospholipid antibodies, were 
demonstrated in the serum or adhering to the surface of SBI. This 
finding is in keeping with the development of massive capsular 
fibrosis and contracture as well as with the induction of autoimmune 
syndromes, especially in predisposed patients. 
 ??
?
3.  
BREAST IMPLANTS AND CTD 
 
3.1 On the aim of this study  
Considering that the presence of the breast implants causes a 
natural foreign body reaction characterized by the infiltration of 
macrophages and T cells, and that these cells are involved in the 
development of CTD in implant carriers, I created a cartoon 
explicating every steps of capsule formation and the cells involved in 
order to understand which immunological pathways can be 
responsible for triggering and developing CTD in predisposed 
patients.8 
  
3.2 The periprosthetic capsule and CTD 
As I said earlier, the capsular formation is a dynamic 
inflammatory process. Nowadays it’s clear that the mechanical 
presence of the implant can transform a “normal foreign body 
reaction” to a chronic inflammatory reaction. This theory is 
confirmed by many histological studies that have described the 
development of granuloma even years later after implantation. 
????????????????????????????????????????????????????????????
8
 I had the idea for this theory three years ago and the long period, taken to develop 
it and to publish the article related, is due to 1) the numerous discussions and 
revisions with Prof. Doria and  my supervisors in order to verify the goodness of 
the theory, 2) the numerous attempts done to find a financial supports to the project 
that I presented, in 2011, to the Ethic Committee for animal testing of Padua 
University. 
 ??
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If in normal subjects this process can lead to capsular 
contracture, in genetically predisposed individuals, chronic inflam-
mation could give rise not only to a fibrotic capsule with subsequent 
capsular contracture, but may also stimulate an autoimmune response 
characterized, for example, by anti-collagen autoantibodies9.  
 
3.2.1 The immunologic steps of the capsule 
 
Since the discovery of mammary capsule it was clear that the 
first cells involved in a foreign body reaction are the macrophages. 
Their presence has been seen by Raso in 1994 and 1995 that 
described numerous mithocondria, cytoplasmatic process and 
vacuole. In 1995 Del Rosario confirmed the presence of CD68+ cells 
known macrophages. 
These observations have been confirmed later in 1999 and 
2001 by Abbondanzo and Kamel. Finally, Raso described, in 
macrophages cytoplasm, silicon material pointing out the phagocytic 
attempt. 
But these are only the first cells, later the lymphocytic cells 
(T and B) take place. The first evidence has been described in 1991 
by Picha et al,  but only 5 ys later Katzin, using the three colours 
????????????????????????????????????????????????????????????
9
 The capsule and  its thickness depend on the material used for the SBI and, most 
important, on the characteristics of the patients, which may present a predisposition 
to an excessive fibroplasia. It is therefore clear, in the final analysis, as the 
periprosthetic fibrous capsule is a physiological and inevitable reaction and that the 
plastic surgeons can only try to delay or avoid the contraction keeping a thin and 
soft capsule and searching for a valid medical and drug therapies. 
 ??
?
flowcytometry, studied their phenotype noting CD4+ T cells. This 
observation has been considered very important because it indirectly 
demonstrated the possible activation of B cells to produce antibodies. 
Recently Wolfram noticed two classes of cells in periprosthetic 
capsule: Treg and Th17 that, as we see later, could be very important 
in the onset of CTDs. 
 
3.2.2 The first step: 
 
 ??
?
Initially the immune system tries to reject the implant, 
inducing a foreign body reaction that due to the implant’s size 
isolates the implant from surrounding tissue making a new tissue (a 
granulation tissue).   
This first step is characterized by infiltration of CD68+ 
macrophages mixed in the inner layer with secretory cells producing 
proteoglycans in order to lubricate the space between the capsule and 
the implant. 
In this stage macrophages produce cytokines such as tumor 
necrosis factor ? (TNF-?), interleukin 1 (IL-1) and interleukin 6 (IL-
6), leading to an acute inflammatory response and recruitment of 
other immune cells including T lymphocytes.  
 
3.2.3 The second step: 
 
 
 ??
?
The T Lymphocytes are reported as CD4+ T helper (Th) cells 
which could be activated by antigens like silica particles derived 
from the implant surface to produce IL-2 and probably IL-6 with the 
consequent activation of B cells and the production of anti-silica 
antibodies observed in capsular biopsies by some authors. 
 
3.2.4 The third and fourth steps: 
?
 
 
?(?
?
TNF-? and tissue growth factor-? (TGF-?), produced by 
macrophages and activated T cells, may stimulate neoangiogenesis 
and fibroblast growth with the formation of proteins such as collagen 
and connective tissue, leading to the transformation of the foreign 
body reaction in a fibrotic capsule. 
 
3.3 The cells and cytokines involved 
 
3.3.1 The cells 
1) Macrophages: monocytes featured by CD68+, the 
macrophages are very mobile phagocytic cells, firstly involved in a 
foreign body reaction. 
Histologically they can be distinguish in two forms depending 
on their state of activation: a) not activated macrophages: round, 
stars-like or fusiform cells with basophil cytoplasm, lysosomes and 
abundant rough endoplasmic reticulum; in this phase they are very 
similar to fibroblasts and recognizable only with a colloidal 
coloration; b) activated macrophages: recognizable for the bigger 
dimension and the presence of phagocytosed material in their 
cytoplasm. They are featured by membrane extensions that allow 
their migration to the inflammatory site. 
Macrophages’ rule is to phagocyte pathogens and to present, 
as APC cells, the antigen to lymphocytes with the aim of avoiding 
infections and stimulating an immunitary response. 
???
?
They produce cytokines like IL-1, IL-6, IL-23 and TNF-? that 
are responsible for the maintenance of the inflammation calling other 
cells like T and B cells.  
In the periprosthetic capsule the macrophages isolate the 
implants from surrounding tissues, and in some cases they are 
present in synovial metaplasia and, producing IL-6, they induce the 
differentiation of T na ve cells into T helper 17. 
 
2) T lymphocytes: histologically featured by an important 
nucleus surrounded by a little cytoplasm, in the capsule these cells 
can be responsible for recognizing the antigens and regulating the 
inflammation. 
 
Treg: having a peripheral differentiation, they are stimulated 
by TGF-? and IL-2 and inhibited by IL-6. Usually they represent 2-
3% of human CD4+ T cells. 
These cells are featured by Foxp3+ and are responsible for 
turning off the inflammatory response and it has been demonstrated 
their reduction or dysfunction in autoimmune disease like 
Rheumatoid Arthritis. 
 
Th17: T helper cells that produce Th17 stimulated by IL-1?, 
IL-6, IL-23 and TGF-?. However the role of the latter is very 
controversial: some authors pointed out a possible, in vitro, 
differentiation without TGF but only in presence of IL-6 and IL-1?. 
? ?
?
Th17 stimulate the synoviocytes to produce VEGF and the 
IL-17 activates IL-6 in synovial compartment creating a positive 
feedback that continuously produce Th17 converting the 
inflammation from acute to chronic. 
In Miastenia Gravis they represent the key for the production 
of autoantibodies. In 2011 Peters et al. demonstrated that the Th17 
derived only by IL-6 and IL-1? could be more pathogenic because of 
the interaction with IL-23 (derived by APC cells like macrophages), 
keeping the inflammation. 
In the last months a possible conversion of Treg into Th17 
has been hypothesized, due to the presence of a high amount of IL-6 
and IL-1?. 
 
3) B cells: responsible for the production of antibodies, after 
the stimulation by the antigen (silicon material in our case), they 
differentiate in plasmablasts and later in plasmacells. The 
plasmacells are histologically featured by bigger dimension, 
excentric oval or round nucleus with a typical chromatine whell-
shaped and the presence of nucleoli. These last two features reflect 
the active production of antibodies. 
 
3.3.2 The cytokines: 
1) IL-1:  is a pleiotropic mediator of the response to injuries 
and infections. Produced by macrophages, dendritic cells, B and T 
cells in peripheral circulation, it stimulates the secretion of G-CSF, 
???
?
TNF-?, IL-6, IL-17 and others. Locally IL-1 is an autocrin and 
paracrin costimulator in the early innate inflammatory and in 
adaptive immune responses. It’s also responsible for the activation of 
autoreactive T cells and stimulates them to migrate thanks to the 
expression of matrix metalloproteinases (MMPs), CD40L and OX40. 
In 2009 IL-1 has been considered the key of the autoimmune 
response Th17 mediated: the IL-1R1 induced by IL-6 is necessary 
for the early differentiation of Th17. 
 
2) IL-6: produced by T cells and macrophages and taking 
part to the acute phase response, this cytokine is historically 
considered proinflammatory and directly fibrotic activating 
fibroblasts to produce collagen and it is directly correlated with skin 
thickness in skin fibrosis. 
It’s responsible for the differentiation of T na ve cells in Th17 
inhibiting the differentiation in Treg cells and it has been involved in 
autoimmune diseases, as SSc, where IL-6 is a marker and has been 
found to be elevated in the bronchoalveolar lavage fluid. 
Finally, notably in 2005 Febbraio M et al. described IL-6 as a 
myokine produced by the muscles cells, expecially during the 
muscular contraction. 
 
3) IL-17: identified as a transcript from a rodent model of T 
cell hybridoma in 1993, IL-17A is a member of IL-17 family which 
???
?
is composed by 6 isoforms from A to F, but only IL-17A and F are 
produced by Th17. 
IL-17 is a proinflammatory cytokine acting as a potent 
mediator in delay type responses; it increases the production of other 
cytokines, as IL-6 or IL-1?, and kemokine, as IL-8, with the aim of 
recruiting immunologic cells, as monocytes, to the site of 
inflammation. 
IL-17 can also activate matrix metalloproteinases (MMPs) 
and inhibit matrix production in chondrocytes and osteoblasts. Its 
overproduction causes a consequent damage of the articulations in 
patients affected by Rheumatoid Arthritis where IL-17 has been 
found in the synovia. 
 
4) TGF-?: the transforming growth factor ? exists in 3 
isoforms but the first (TGF-?1) is the most common in immunitary 
response. Its role is to regulate inflammation recruiting cells like 
monocytes, lymphocytes, neutrophils and fibroblasts and stimulating 
the differentiation of T na ve cells into Treg and Th17 (in this latter 
case TGF interacts with other cytokines as IL-6 and IL-1?). In the 
meantime it can inhibit GMCSF (Granulocyte Macrophage colony 
stimulating factor) with  a consequent downregulation of monocytes’ 
response. 
 
 
 
???
?
It’s also profibrotic: 
1) it induces the Fibroblast Growth Factor;  
2) it activates fibroblasts to produce collagen;  
3) it reduces the production of enzymes that are responsible 
for the degradation of the  Extracellular Matrix. 
Using indirect immunohistochemistry, Kuhn et al. detected 
TGF-?1 and TGF-?2 in all of the fibrotic capsules.  
 
5) TNF-?: involved in the acute phase of the inflammation, 
it’s produced by macrophages and other cells like CD4+ T cells and 
fibroblasts. This cytokine is involved in the production of IL-6 and 
its presence can increase IL-17. 
It interacts with IL-1 and IL-6 with the aim of stimulating 
chemotaxis and phagocytosis. 
In 2010 TNF-? has been involved in capsular contracture: 
Tan et al described an increased expression of this cytokine in the 
inflammatory response correlated with capsular contracture. In this 
article TNF-? was localized in fibroblasts, macrophages and 
extracellularly close to the breast implant. 
???
?
???
?
4.  
THE ‘THEORY’ 
 
4.1 Normal Subjects and predisposed patients 
Based on the immunological steps of the capsular formation, 
cytokines, especially TGF-?, and the new class of  lymphocytes 
Th17 seem to play a major role in the development of CTD induced 
by SBI. In fact, IL-1 and IL-6 have been implicated in the 
differentiation of Th cells into Th17, which produce IL-17, and seem 
to be responsible not only for the transformation from acute to 
chronic inflammatory responses, but also for the onset and 
maintenance of autoimmune diseases such as Rheumatoid Arthritis. 
The balance between Treg and Th17 cells is a critical issue in 
maintaining an inflammatory process and preventing an autoimmune 
response. In a normal subject the activation of fibroblasts, resulting 
in deposition of extracellular matrix (ECM), leads to a down 
regulation of the inflammatory reaction and its transformation into a 
fibrotic reaction. However, in genetically predisposed individuals the 
continuous stimulation, due to the presence of the implant, leads to a 
perpetuation of an immune inflammatory response. 
The continuous activation of macrophages and production of 
TNF-?, IL-1, IL-6 prolongs the inflammatory response with 
production of large amounts of Th17.  Production of IL-1 and IL-2 
promotes the switch in Treg/Th17 cell balance in favor of Th17 cells. 
???
?
TGF-? stimulates the overproduction of IL-6 and fibroblast 
growth factor (FGF), resulting in fibroblast proliferation and ECM 
deposition. Specifically, TGF-?, in addition to stimulating 
macrophages with positive feedback, is able to induce the 
differentiation of fibroblasts into myofibroblasts which present alpha 
smooth muscle actin in the cytoskeleton and are responsible for 
contraction of the scar and deposition of proteoglycans and collagen 
III. Activated macrophages and fibroblasts produce angiotensin II, 
which, by means of Nicotinamide Adenine Dinucleotide Phosphate 
(NADPH), leads to further production of TGF-?1 and subsequent 
reactivation of the inflammatory process described above. 
TGF-?1 and IL-6 can, in turn, induce the differentiation of 
na ve Th cells, which have never come into contact with silicone 
before, into Th17 by activating RORC2 gene. 
Notably, the presence of Th17, the over expression of TGF-
?1, and the overproduction of fibroblasts and ECM (collagen and 
proteoglycans III), may be responsible, in susceptible individuals, for 
a perpetuation of the inflammatory reaction which locally can lead to 
capsular contracture and at the systemic level may contribute to 
triggering autoimmune diseases, especially SSc.  
This autoimmune disease is characterized by the deposition of 
procollagen III and proteoglycans in the skin, lungs, heart and other 
organs, and seems to be related to fibroblast proliferation and TGF-? 
gene over-expression which could stimulate fibroblasts, in an 
autocrine fashion, to produce more collagen. 
???
?
 
 
 
 
 
?(?
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Legenda:  Immunological response following breast implants depends on 
genetic background of patients:  
A) normal subjects with local reaction: notice the temporary stimulation 
of immune inflammatory reaction and the subsequent marked response of 
Treg cells with moderate production of collagen fibers and inhibition of 
Th17 production;  
B) genetically predisposed subjects with systemic reaction: notice the 
continuous stimulation of the immune inflammatory reaction with 
consequent overproduction of collagen fibers and lower activation of Treg 
cells and their inhibition by Th17 
 
4.2 Potential treatment  
The involvement of TGF-? could open many new approaches 
to the therapy of fibrotic capsule and surrounding inflammation. 
Using a rat model, it has been shown that the local application of 
oligonucleotides targeting Connective Tissue Growth Factor (CTGF) 
and TGF-? can reduce CTGF and capsular formation.  
More recently Zimman et al.  have noted a reduction of TGF-
?1, anticollagen III monoclonal autoantibodies and periprosthetic 
fibrosis, in rats treated with angiotensin converting enzyme inhibitors 
(enalapril) which block the renin-angiotensin system and 
consequently the inflammatory and profibrotic effects of angiotensin 
II. 
???
?
Notably, 9-cis-retinoic acid, an antifibrotic drug, increased 
COX2 expression and PGE2 production, inhibiting the expression of 
CTGF as well as type-I and -III collagen in scleroderma cultured 
fibroblasts. 
The use of leukotriene receptor antagonists, zafirlukast and 
montelukast, which showed antifibrotic potential, is controversial. 
Initially developed as a treatment for asthma, zafirlukast was 
demonstrated to reduce capsular thickness impairing collagen 
density. Even this effect could be useful in order to prevent capsular 
fibrosis and contracture. However, there are some reports on the 
occurrence of Churg-Strauss syndrome in patients treated with 
leukotriene receptor antagonists and a direct immunomodulatory role 
for these drugs in the development of vasculitis, has been postulated. 
Recently, Lina et al. reported a reverse in the Th1/Th2, 
Th17/Treg imbalance in patients with RA treated with a therapeutic 
strategy based on the combined treatment with Methotrexate (MTX) 
and Etanercept. The authors demonstrated that Etanercept and MTX 
play an immunomodulatory role on the cytokines involved in the 
capsular process (IL-1, IL-6, TNF-?, TGF-? and IL-17), ameliorating 
RA by normalizing the imbalance between Th17 and Treg. 
Thus, some drugs might play a role by inhibiting not only the 
local but also the systemic inflammatory responses. 
 
? ?
?
???
?
5.  
CONCLUSION 
Although the causal role of SBI on CTD cannot be considered 
conclusive, it can be speculated that some genetically predisposed 
individuals may develop CTD because of the stimulation provided by 
a foreign body. The continuous stimulation of the immune system 
might also explain why the lag-time between SBI and CTD onset can 
vary from months to years. The possibility of using new therapeutic 
strategies could reduce both the risk of capsular contraction and 
autoimmune diseases10. 
????????????????????????????????????????????????????????????
?(? MY PROJECT: in order to demonstrate in vivo the goodness of the ‘theory’ 
exposed above and to find a therapeutic target, in 2011 I presented an experimental 
research, based on an animal model, that has been approved by the Ethic 
Committee for animal testing of Padua University. Unfortunately the lack of 
financial supports and of cooperation (proposed by prof. Doria) with Dr. 
Shoenfeld, who received the text of the project, don’t allow me to complete the 
study. 
?
???
?
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?
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